MR-guided whole-pelvic prostate SBRT shows favorable toxicity with optional focal boosting
In 77 high-risk prostate patients, five-fraction adaptive pelvic SBRT produced 6.9% late grade ≥2 GU and 9.7% GI toxicity.
In 77 high-risk prostate patients, five-fraction adaptive pelvic SBRT produced 6.9% late grade ≥2 GU and 9.7% GI toxicity.
Uncertainty-guided post-processing increased MRI-based liver metastasis detection sensitivity from 84.6% to 98.1%, while generating additional false-positive candidates.
Across 40 Unity SBRT plans, OCTAVIUS 4D achieved 98.3% mean local gamma passing with sub-degree angular agreement.
No grade 3 toxicity occurred after five-fraction MR-guided salvage radiotherapy, while urinary and bowel quality-of-life scores remained stable.
gPRIDE closely matched Monte Carlo calculations for most anatomies and completed MRI-guided proton dose calculations within 13.7 seconds.
MRI-guided SBRT with 2-mm margins reduced low- and intermediate-dose exposure of neurovascular bundles and pudendal arteries versus CT-guided treatment.
Magnetic resonance-only prostate simulation achieved 96.80% local gamma agreement using synthetic computed tomography for dose calculation.
N4 bias correction with z-score normalization produced the most stable radiomic features on a 0.35 tesla magnetic resonance linear accelerator.
Daily magnetic resonance-informed adaptation increased target coverage by 14% and reduced bowel dose by 7% for pelvic lymph node metastases.
Standardized two-hour fasting produced reproducible stomach volumes in only 42% of patients receiving magnetic resonance-guided pancreatic stereotactic radiotherapy.